The American Journal of Medicine
Volume 121, Issue 4 , Pages 316-323, April 2008

Delay in Presentation and Reperfusion Therapy in ST-Elevation Myocardial Infarction

  • Henry H. Ting, MD, MBA

      Affiliations

    • Division of Cardiovascular Diseases and Mayo Clinic College of Medicine, Mayo Clinic, Rochester, Minn
    • Corresponding Author InformationRequests for reprints should be addressed to Henry H. Ting, MD, MBA, Division of Cardiovascular Diseases, Mayo Clinic, 200 First Street SW, Rochester, MN 55905.
  • ,
  • Elizabeth H. Bradley, PhD

      Affiliations

    • Division of Health Policy and Administration, Department of Epidemiology and Public Health, Yale University School of Medicine and Yale-New Haven Hospital Center for Outcomes Research and Evaluation, New Haven, Conn
    • Robert Wood Johnson Clinical Scholars Program, Yale University School of Medicine and Yale-New Haven Hospital Center for Outcomes Research and Evaluation, New Haven, Conn
  • ,
  • Yongfei Wang, MS

      Affiliations

    • Section of Cardiovascular Medicine, Yale University School of Medicine and Yale-New Haven Hospital Center for Outcomes Research and Evaluation, New Haven, Conn
  • ,
  • Brahmajee K. Nallamothu, MD, MPH

      Affiliations

    • VA Health Services Research and Development Center for Excellence and Department of Medicine, University of Michigan Medical School, Ann Arbor.
  • ,
  • Bernard J. Gersh, MB, ChB, DPhil

      Affiliations

    • Division of Cardiovascular Diseases and Mayo Clinic College of Medicine, Mayo Clinic, Rochester, Minn
  • ,
  • Veronique L. Roger, MD, MPH

      Affiliations

    • Division of Cardiovascular Diseases and Mayo Clinic College of Medicine, Mayo Clinic, Rochester, Minn
  • ,
  • Judith H. Lichtman, PhD

      Affiliations

    • Division of Health Policy and Administration, Department of Epidemiology and Public Health, Yale University School of Medicine and Yale-New Haven Hospital Center for Outcomes Research and Evaluation, New Haven, Conn
  • ,
  • Jeptha P. Curtis, MD

      Affiliations

    • Section of Cardiovascular Medicine, Yale University School of Medicine and Yale-New Haven Hospital Center for Outcomes Research and Evaluation, New Haven, Conn
  • ,
  • Harlan M. Krumholz, MD, SM

      Affiliations

    • Division of Health Policy and Administration, Department of Epidemiology and Public Health, Yale University School of Medicine and Yale-New Haven Hospital Center for Outcomes Research and Evaluation, New Haven, Conn
    • Robert Wood Johnson Clinical Scholars Program, Yale University School of Medicine and Yale-New Haven Hospital Center for Outcomes Research and Evaluation, New Haven, Conn
    • Section of Cardiovascular Medicine, Yale University School of Medicine and Yale-New Haven Hospital Center for Outcomes Research and Evaluation, New Haven, Conn

Abstract 

Background

We studied the relationship between longer delays from symptom onset to hospital presentation and the use of any reperfusion therapy, door-to-balloon time, and door-to-drug time.

Methods

Cohort study of patients with ST-elevation myocardial infarction enrolled in the National Registry of Myocardial Infarction from January 1, 1995 to December 31, 2004. Delay in hospital presentation was categorized into 1-hour intervals as ≤1 hour, >1-2 hours, >2-3 hours, etc, up to >11-12 hours. The study analyzed 3 groups: 440,398 patients for the association between delay and use of any reperfusion therapy; 67,207 patients for the association between delay and door-to-balloon time; 183,441 patients for the association between delay and door-to-drug time.

Results

In adjusted analyses, patients with longer delays between symptom onset and hospital presentation were less likely to receive any reperfusion therapy, had longer door-to-balloon times, and had longer door-to-needle times (all P <.0001 for linear trend). For patients presenting ≤1 hour, >1-2 hours, >2-3 hours, >9-10 hours, >10-11 hours, and >11-12 hours after symptom onset, the use of any reperfusion therapy were 77%, 77%, 73%, 53%, 50%, and 46%, respectively. Door-to-balloon times were 99, 101, 106, 123, 125, and 123 minutes, respectively, and door-to-drug times were 33, 34, 36, 46, 44, and 47 minutes, respectively.

Conclusions

Longer delays from symptom onset to hospital presentation were associated with reduced likelihood of receiving primary reperfusion therapy, and even among those treated, late presenters had significantly longer door-to-balloon and door-to-drug times.

Keywords: Angioplasty, Fibrinolysis, Myocardial infarction, Quality, Reperfusion

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported by grant R01 HL072575 from the National Heart, Lung, and Blood Institute, Bethesda, Maryland.

PII: S0002-9343(07)01190-4

doi:10.1016/j.amjmed.2007.11.017

The American Journal of Medicine
Volume 121, Issue 4 , Pages 316-323, April 2008